184 related articles for article (PubMed ID: 17583861)
1. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
González-Gutiérrez JL; Gobartt AL;
Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
[TBL] [Abstract][Full Text] [Related]
2. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
Gil-Néciga E; Gobartt AL;
Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
[TBL] [Abstract][Full Text] [Related]
4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
6. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
7. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).
Gauthier S; Juby A; Dalziel W; Réhel B; Schecter R;
Curr Med Res Opin; 2010 May; 26(5):1149-60. PubMed ID: 20230208
[TBL] [Abstract][Full Text] [Related]
8. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
[TBL] [Abstract][Full Text] [Related]
9. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
10. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
12. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study of the effectiveness and tolerability of a procedure involving slow dose-escalation of rivastigmine in patients with mild or moderate Alzheimer-type dementia: the SCALEX study].
Agüera-Ortiz LF; Ramos-García M; Gobartt AL;
Rev Neurol; 2008 May 1-15; 46(9):517-24. PubMed ID: 18446692
[TBL] [Abstract][Full Text] [Related]
14. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Farlow MR; Lilly ML;
BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
[TBL] [Abstract][Full Text] [Related]
16. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH; Schmand BA
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):545-51. PubMed ID: 17109476
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine for Alzheimer's disease.
Desai AK; Grossberg GT
Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
[TBL] [Abstract][Full Text] [Related]
18. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.
Boada M; Arranz FJ
Dement Geriatr Cogn Disord; 2013; 35(1-2):23-33. PubMed ID: 23306147
[TBL] [Abstract][Full Text] [Related]
19. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
Muhlack S; Przuntek H; Müller T
Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
[TBL] [Abstract][Full Text] [Related]
20. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
